Skip to main content

Market Overview

Why The Amgen/Regeneron Patent Saga Is Far From Over

Why The Amgen/Regeneron Patent Saga Is Far From Over

Despite the District Court’s ruling in favor of Amgen, Inc. (NASDAQ: AMGN) over cholesterol drug Praluent, Leerink believes the patent dispute with Regeneron Pharmaceuticals Inc (NASDAQ: REGN) and Sanofi SA (ADR) (NYSE: SNY) is far from over given the possibility of appeal by these firms and Amgen’s firm stance against a settlement.

For Sanofi, the permanent injunction adds incremental uncertainty to its long-term top-line growth. Analyst Seamus Fernandez said completely removing Praluent U.S. sales would reduce his €91 price target by €3–€3.5.

“If the permanent injunction is enforced by the end of this month, which would surprise us, we would expect a substantial reduction of marketing costs behind the currently unprofitable franchise,” Fernandez wrote in a note.

Lackluster Sales

Meanwhile, sales of both Praluent and Amgen's Repatha have been lackluster since launch, and the analyst expects less than €200 million in U.S. Praluent sales for FY 2017. So, it would be positive for Sanofi earnings if Praluent were removed completely along with U.S. promotional spend.

“Assuming the R&D expenses remain unchanged, but removing U.S. Praluent sales and the associated SG&A cost would likely increase EPS by ~€0.03–0.05 in 2017E/18E. We currently forecast 2017 EPS of €5.53/shr,” Fernandez highlighted.

Fernandez also noted that it may not be financially viable for Sanofi/Regeneron to consider a high royalty payment of 20 percent or more to Amgen as the PCSK9 market opportunity has turned out be smaller than initial forecast.

“Similarly, such a royalty in a substantially smaller market likely would deliver much less value for AMGN than eliminating a competitor for market share with the ability to price Repatha without any competitive threat,” Fernandez added.

Fernandez has a Market Perform rating on Amgen, while being Outperform on both Sanofi and Regeneron.

At Last Check

  • Shares of Amgen were up 0.46 percent at $157.50.
  • Shares of Regeneron were down 1.52 percent at $353.23.
  • Shares of Sanofi were up 1.18 percent at $40.82.

Latest Ratings for AMGN

Apr 2021Morgan StanleyMaintainsOverweight
Apr 2021OppenheimerMaintainsOutperform
Mar 2021BarclaysMaintainsEqual-Weight

View More Analyst Ratings for AMGN
View the Latest Analyst Ratings


Related Articles (AMGN + REGN)

View Comments and Join the Discussion!

Posted-In: Analyst Color Biotech Long Ideas News Price Target Reiteration Legal Analyst Ratings Best of Benzinga

Latest Ratings

ALHCB of A SecuritiesInitiates Coverage On29.0
BWAYNorthland Capital MarketsInitiates Coverage On15.0
STLB. Riley FBRDowngrades26.0
PDDChina RenaissanceDowngrades
OVIDCantor FitzgeraldDowngrades4.0
View the Latest Analytics Ratings
Don't Miss Any Updates!
News Directly in Your Inbox
Subscribe to:
Benzinga Premarket Activity
Get pre-market outlook, mid-day update and after-market roundup emails in your inbox.
Market in 5 Minutes
Everything you need to know about the market - quick & easy.
Fintech Focus
A daily collection of all things fintech, interesting developments and market updates.
Everything you need to know about the latest SPAC news.
Thank You

Thank you for subscribing! If you have any questions feel free to call us at 1-877-440-ZING or email us at